DOI:
10.1055/s-00000161
The Journal of Knee Surgery
LinksClose Window
References
Perzborn E, Kubitza D, Misselwitz F.
Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders.
Hamostaseologie 2007;
27 (04) 282-289
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.